<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="acp" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">acp</book-part-id>
      <title-group>
        <title>Aceruloplasminemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Miyajima</surname>
            <given-names>Hiroaki</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>First Department of Medicine<break/>Hamamatsu University School of Medicine<break/>Hamamatsu, Japan</aff>
          <email>miyajima@hama-med.ac.jp</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>12</day>
          <month>8</month>
          <year>2003</year>
        </date>
        <date date-type="updated">
          <day>5</day>
          <month>11</month>
          <year>2015</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pfic" document-type="chapter">ATP8B1 Deficiency</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="achon1b" document-type="chapter">Achondrogenesis Type 1B</related-object>
      <abstract id="acp.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Aceruloplasminemia is characterized by iron accumulation in the brain and viscera. The clinical triad of retinal degeneration, diabetes mellitus (DM), and neurologic disease is seen in individuals ranging from age 25 years to older than 70 years. The neurologic findings of movement disorder (blepharospasm, grimacing, facial and neck dystonia, tremors, chorea) and ataxia (gait ataxia, dysarthria) correspond to regions of iron deposition in the brain. Individuals with aceruloplasminemia often present with anemia prior to onset of DM or obvious neurologic problems. Cognitive dysfunction including apathy and forgetfulness occurs in more than half of individuals with this condition.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Aceruloplasminemia, a disorder of iron metabolism caused by the complete absence of ceruloplasmin ferroxidase activity, is caused by pathogenic variants in <italic toggle="yes">CP</italic>, which encodes ceruloplasmin. The diagnosis of aceruloplasminemia in a symptomatic individual relies on demonstration of the absence of serum ceruloplasmin and some combination of the following: low serum copper concentration, low serum iron concentration, high serum ferritin concentration, and increased hepatic iron concentration. The diagnosis is strongly supported by characteristic MRI findings of abnormal low intensities reflecting iron accumulation in the brain (striatum, thalamus, dentate nucleus) and liver on both T<sub>1</sub>- and T<sub>2</sub>-weighted images.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Iron chelating agents (i.e., desferrioxamine or deferasirox) to decrease serum ferritin concentration, decrease brain and liver iron stores, and prevent progression of neurologic signs/symptoms in symptomatic individuals with blood hemoglobin concentration higher than 9 g/dL; combined IV desferrioxamine and fresh-frozen human plasma (FFP) is effective in decreasing iron content in the liver; repetitive FFP treatment can improve neurologic signs/symptoms; antioxidants such as vitamin E may be used along with a chelator or oral administration of zinc to prevent tissue damage, particularly to the liver and pancreas.</p>
          <p><italic toggle="yes">Surveillance:</italic> Annual glucose tolerance test starting at age 15 years to evaluate for the onset of diabetes mellitus; ECG evaluation early in the course of the disease; evaluation of thyroid and liver function and complete blood count annually starting at the time of diagnosis.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Iron supplements.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> If the pathogenic variants in the family are known, molecular genetic testing of asymptomatic sibs of a proband allows for early diagnosis and initiation of surveillance and treatment. If pathogenic variants are unknown, monitoring of serum concentrations of hemoglobin and hemoglobin A1c in asymptomatic sibs is recommended.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Aceruloplasminemia is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">CP</italic> pathogenic variants in the family have been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="acp.Diagnosis">
        <title>Diagnosis</title>
        <p>Aceruloplasminemia is characterized by iron accumulation in the brain and viscera.</p>
        <sec id="acp.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Aceruloplasminemia <bold>should be suspected</bold> in individuals with characteristic MRI findings and more than one of the following findings:</p>
          <list list-type="bullet">
            <list-item>
              <p>Retinal degeneration</p>
            </list-item>
            <list-item>
              <p>Diabetes mellitus (DM)</p>
            </list-item>
            <list-item>
              <p>Anemia</p>
            </list-item>
            <list-item>
              <p>Neurologic disturbance (ataxia, involuntary movement)</p>
            </list-item>
          </list>
          <p><bold>MRI.</bold> Abnormal low intensities in the liver as well as the striatum, thalamus, and dentate nucleus of the brain on T<sub>1</sub>- and T<sub>2</sub>-weighted images are consistent with iron deposition and support a diagnosis of aceruloplasminemia (see <xref ref-type="fig" rid="acp.F1">Figure 1</xref>).</p>
          <p><bold>Retinal degeneration.</bold> Ophthalmologic examinations typically reveal evidence of early-onset macular degeneration [<xref ref-type="bibr" rid="acp.REF.dunaief.2005.1062">Dunaief et al 2005</xref>]. Ninety-three percent of Japanese individuals with aceruloplasminemia demonstrate retinal degeneration [<xref ref-type="bibr" rid="acp.REF.miyajima.2003.205">Miyajima et al 2003</xref>]. Visual acuity is not disturbed. Several small yellowish opacities are scattered over grayish atrophy of the retinal pigment epithelium. Fluorescein angiography demonstrates window defects corresponding to the yellowish opacities. These findings differ from diabetic retinopathy [<xref ref-type="bibr" rid="acp.REF.yamaguchi.1998.11">Yamaguchi et al 1998</xref>].</p>
        </sec>
        <sec id="acp.Laboratory_Testing">
          <title>Laboratory Testing</title>
          <p><bold>Serum ceruloplasmin</bold> is not detectable by Western blot analysis (normal serum concentration: 21-36 mg/dL).</p>
          <p><bold>Serum copper concentration</bold> is lower than10 &#x000b5;g/dL (normal range: 70-125 &#x000b5;g/dL).</p>
          <p><bold>Serum iron concentration</bold> is lower than 45 &#x000b5;g/dL (normal range: male 60-180 &#x000b5;g/dL; female 60-140 &#x000b5;g/dL).</p>
          <p><bold>Serum ferritin concentration</bold> is 850-4000 ng/mL (normal range: male 45-200 ng/mL; female 30-100 ng/mL).</p>
          <p><bold>Plasma ceruloplasmin ferroxidase activity</bold> is not detectable using the method described by <xref ref-type="bibr" rid="acp.REF.erel.1998.2313">Erel [1998]</xref>. (normal activity is 500-680 U/L).</p>
          <p><bold>Pathologic diagnosis.</bold> Visceral organs, especially the liver, pancreas, and heart, have iron deposition:</p>
          <list list-type="bullet">
            <list-item>
              <p>The liver shows no cirrhotic changes. The iron content in the liver is greater than the iron content in the brain. The hepatic iron concentration (HIC) is determined in &#x000b5;mol/g of dry weight. The hepatic iron index (HII) is then calculated by dividing the hepatic iron concentration by the age (in years) of the individual. Normal individuals have an HII of 1.1 or less; more than 80% of individuals with aceruloplasminemia have an HII greater than 1.3. (HIC [&#x000b5;g/g dry weight] 56 = HIC [&#x000b5;mol/g dry weight], HIC [&#x000b5;mol/g dry weight]/age [years] = HII).</p>
            </list-item>
            <list-item>
              <p>Islet beta cells demonstrate iron deposition, which results in diabetes mellitus.</p>
            </list-item>
            <list-item>
              <p>The distribution in order of iron level in the brain is globus pallidus &#x0003e; putamen &#x0003e; cerebral cortex &#x0003e; cerebellar cortex. Severe iron overload and extensive neuronal loss are observed in the basal ganglia, while iron deposition and neuronal cell loss are trivial in the frontal cortices. The cerebellar cortex shows marked loss of Purkinje cells. Iron deposition is more prominent in the astrocytes than in the neurons. Astrocytic deformity and globular structures are characteristic features in brains of individuals with aceruloplasminemia. The globular structures in the astrocytes are seen in proportion to the degree of iron deposition [<xref ref-type="bibr" rid="acp.REF.kaneko.2002.1069">Kaneko et al 2002</xref>, <xref ref-type="bibr" rid="acp.REF.miyajima.2003.345">Miyajima 2003</xref>, <xref ref-type="bibr" rid="acp.REF.oide.2006.170">Oide et al 2006</xref>].</p>
            </list-item>
          </list>
        </sec>
        <sec id="acp.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of aceruloplasminemia <bold>is established</bold> in a proband on identification of biallelic pathogenic variants in <italic toggle="yes">CP</italic> on molecular genetic testing (see <xref ref-type="table" rid="acp.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Molecular testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">CP</italic> is performed first and followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">CP</italic> and other genes of interest (see <xref ref-type="sec" rid="acp.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included and sensitivity of multi-gene panels vary by laboratory and over time.</p>
            </list-item>
            <list-item>
              <p><bold>More comprehensive genomic testing</bold> (when available) including exome sequencing, genome sequencing, and mitochondrial sequencing may be considered if serial single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of aceruloplasminemia. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
            </list-item>
          </list>
          <table-wrap id="acp.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Aceruloplasminemia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">CP</italic>
                  </td>
                  <td headers="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;92%&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>5</sup></td>
                  <td headers="hd_h_acp.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown&#x000a0;<sup>6</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="acp.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="acp" object-id="acp.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="acp.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="acp.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="acp.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="acp.TF.1.4">
                <label>4. </label>
                <p>Individuals of Japanese heritage [<xref ref-type="bibr" rid="acp.REF.miyajima.1999.617">Miyajima et al 1999</xref>]. Sequence analysis identifies at least one pathogenic variant in all individuals with abnormal low intensity areas in both the basal ganglia and the liver on MRI.</p>
              </fn>
              <fn id="acp.TF.1.5">
                <label>5. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="acp.TF.1.6">
                <label>6. </label>
                <p>No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="acp.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="acp.Clinical_Description">
          <title>Clinical Description</title>
          <p>Clinical manifestations of aceruloplasminemia are a triad of retinal degeneration, diabetes mellitus (DM), and neurologic signs/symptoms [<xref ref-type="bibr" rid="acp.REF.miyajima.2003.345">Miyajima 2003</xref>]. Individuals with aceruloplasminemia often present with anemia prior to onset of DM or neurologic signs/symptoms. Phenotypic expression varies even within families.</p>
          <p>A summary of clinical manifestations in 71 Japanese individuals is shown in <xref ref-type="table" rid="acp.T.clinical_manifestationsage_at_onse">Table 2</xref>. The manifestations (in order of frequency) are anemia, retinal degeneration, diabetes mellitus, and neurologic signs/symptoms. The neurologic signs/symptoms correspond to regions of brain iron accumulation and include ataxia, involuntary movement, parkinsonism, and cognitive dysfunction. Molecular genetic testing of <italic toggle="yes">CP</italic> on a research basis allowed for confirmation of the diagnosis in individuals with atypical clinical findings, further expanding the phenotypic spectrum [<xref ref-type="bibr" rid="acp.REF.miyajima.2003.205">Miyajima et al 2003</xref>, <xref ref-type="bibr" rid="acp.REF.kono.2012.1190">Kono 2012</xref>, <xref ref-type="bibr" rid="acp.REF.kono.2015">Kono &#x00026; Miyajima 2015</xref>]</p>
          <table-wrap id="acp.T.clinical_manifestationsage_at_onse" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Clinical Manifestations/Age at Onset in 71 Individuals with Aceruloplasminemia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="2" align="left" scope="colgroup" rowspan="1">Clinical Manifestations</th>
                  <th id="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Age at Onset of Manifestation</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="2" align="left" scope="col" rowspan="1">Anemia (80%)</td>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Diabetes mellitus (70%)</td>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;30 yrs: 18%<break/>30-39 yrs: 35%<break/>40-49 yrs: 31%<break/>&#x0003e;50 yrs: 16%</td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="2" align="left" scope="row" rowspan="1">Retinal degeneration (76%)</td>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">At least &#x0003e;20 yrs</td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">Neurologic symptoms (68%)</td>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1">Ataxia (71%) incl dysarthria, gait ataxia, limb ataxia, nystagmus</td>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_2" rowspan="4" valign="middle" align="left" colspan="1">&#x0003c;40 yrs: 7%<break/>40-49 yrs: 38%<break/>50-59 yrs: 42%<break/>&#x0003e;60 yrs: 13%</td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Involuntary movement (64%) incl dystonia (blepharospasm, grimacing, neck dystonia), tremors, chorea</td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Parkinsonism (20%) incl rigidity, akinesia</td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.clinical_manifestationsage_at_onse_1_1_1_1" valign="middle" colspan="1" align="left" scope="col" rowspan="1">Cognitive dysfunction (60%) incl apathy, forgetfulness</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>From <xref ref-type="bibr" rid="acp.REF.kono.2015">Kono &#x00026; Miyajima [2015]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <sec id="acp.Additional_Findings">
            <title>Additional Findings</title>
            <p>
              <bold>Laboratory findings</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Undetectable serum ceruloplasmin</p>
              </list-item>
              <list-item>
                <p>Elevated serum ferritin</p>
              </list-item>
              <list-item>
                <p>Decreased serum iron</p>
              </list-item>
              <list-item>
                <p>Iron refractory microcytic anemia</p>
              </list-item>
              <list-item>
                <p>Low serum copper and normal urinary copper levels</p>
              </list-item>
            </list>
            <p>
              <bold>MRI (magnetic resonance imaging) findings</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Low intensity on both T<sub>1</sub>- and T<sub>2</sub>-weighted MRI in the liver and the basal ganglia, including the caudate nucleus, putamen and pallidum, and the thalamus</p>
              </list-item>
            </list>
            <p>
              <bold>Liver biopsy results</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Excess iron accumulation (&#x0003e;1200 &#x000b5;g/gram dry weight) within hepatocytes and reticuloendothelial cells</p>
              </list-item>
              <list-item>
                <p>Normal hepatic architecture and histology without cirrhosis or fibrosis</p>
              </list-item>
              <list-item>
                <p>Normal copper accumulation</p>
              </list-item>
            </list>
            <p>Neuropathology in the brain includes bizarrely formed astrocytes and grumose or foamy spheroid bodies [<xref ref-type="bibr" rid="acp.REF.kaneko.2002.1069">Kaneko et al 2002</xref>, <xref ref-type="bibr" rid="acp.REF.oide.2006.170">Oide et al 2006</xref>].</p>
          </sec>
        </sec>
        <sec id="acp.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>No clear genotype-phenotype correlation exists for aceruloplasminemia.</p>
          <p>Individuals with typical clinical signs/symptoms who are compound heterozygotes for the <xref ref-type="table" rid="acp.T.cp_pathogenic_variants_discussed_i">p.His978Gln</xref> pathogenic variant showed normal serum ceruloplasmin concentrations but absent ferroxidase activity [<xref ref-type="bibr" rid="acp.REF.takeuchi.2002.543">Takeuchi et al 2002</xref>]. Another individual with retinal degeneration and diabetes mellitus who was homozygous for the <xref ref-type="table" rid="acp.T.cp_pathogenic_variants_discussed_i">p.Gly969Ser</xref> pathogenic variant showed a decrease in serum ceruloplasmin concentration because of the secretion of only apoceruloplasmin without any ferroxidase activity [<xref ref-type="bibr" rid="acp.REF.kono.2006b.240">Kono et al 2006b</xref>]. This is a caveat in making the diagnosis on normal ceruloplasmin concentrations alone.</p>
        </sec>
        <sec id="acp.Nomenclature">
          <title>Nomenclature</title>
          <p>Aceruloplasminemia was originally called familial apoceruloplasmin deficiency [<xref ref-type="bibr" rid="acp.REF.miyajima.1987.761">Miyajima et al 1987</xref>].</p>
        </sec>
        <sec id="acp.Prevalence">
          <title>Prevalence</title>
          <p>The serum ceruloplasmin concentrations of about 5,000 adults undergoing medical examination were screened (<xref ref-type="table" rid="acp.T.frequencies_of_aceruloplasminemia">Table 3</xref>). The prevalence of aceruloplasminemia was estimated at one in 2,000,000 in non-consanguineous marriages in Japan [<xref ref-type="bibr" rid="acp.REF.miyajima.1999.617">Miyajima et al 1999</xref>].</p>
          <table-wrap id="acp.T.frequencies_of_aceruloplasminemia" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Frequencies of Aceruloplasminemia</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Parental Relatedness</th>
                  <th id="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Homozygotes</th>
                  <th id="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Heterozygotes</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Non-consanguineous</td>
                  <td headers="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">4.90 x 10<sup>-7</sup></td>
                  <td headers="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1.40 x 10<sup>-3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Consanguineous</td>
                  <td headers="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3.29 x 10<sup>-6</sup></td>
                  <td headers="hd_h_acp.T.frequencies_of_aceruloplasminemia_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1.39 x 10<sup>-3</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>From <xref ref-type="bibr" rid="acp.REF.miyajima.1999.617">Miyajima et al [1999]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Heterozygotes for the ceruloplasmin gene were estimated to account for 0.1% of individuals with diabetes in Japan [<xref ref-type="bibr" rid="acp.REF.daimon.1997.678">Daimon et al 1997</xref>].</p>
        </sec>
      </sec>
      <sec id="acp.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotype other than those discussed in this <italic toggle="yes">GeneReview</italic> is currently known to be associated with pathogenic variants in <italic toggle="yes">CP</italic>.</p>
      </sec>
      <sec id="acp.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><related-object link-type="booklink" source-id="gene" document-id="nbia-ov" document-type="chapter">Neurodegeneration with brain iron accumulation</related-object> (NBIA) is a group of progressive extrapyramidal disorders with radiographic evidence of focal iron accumulation in the brain, usually the basal ganglia. Later-onset, slowly progressive NBIA includes atypical <related-object link-type="booklink" source-id="gene" document-id="pkan" document-type="chapter">pantothenate kinase-associated neurodegeneration</related-object> (PKAN) [<xref ref-type="bibr" rid="acp.REF.hayflick.2003.33">Hayflick et al 2003</xref>], which results from pathogenic variants in <italic toggle="yes">PANK2</italic> [<xref ref-type="bibr" rid="acp.REF.zhou.2001.345">Zhou et al 2001</xref>]; <related-object link-type="booklink" source-id="gene" document-id="neuroferritin" document-type="chapter">neuroferritinopathy</related-object>, a disorder associated with pathogenic variants in <italic toggle="yes">FTL</italic>; and aceruloplasminemia.</p>
        <p>Low serum concentration of ceruloplasmin is not specific for aceruloplasminemia. Ceruloplasmin deficiency is a characteristic feature in copper metabolic disorders, including Wilson disease and Menkes disease:</p>
        <list list-type="bullet">
          <list-item>
            <p>In <related-object link-type="booklink" source-id="gene" document-id="wilson" document-type="chapter">Wilson disease</related-object>, an inability to transfer copper into the ceruloplasmin precursor protein, apoceruloplasmin, and a decrease in biliary copper excretion results in serum ceruloplasmin deficiency and excess copper accumulation.</p>
          </list-item>
          <list-item>
            <p>In Menkes disease, copper absorption from the intestine is decreased, leading to copper and ceruloplasmin deficiencies in the body. In contrast, aceruloplasminemia is an iron metabolic disorder in which ceruloplasmin deficiency is caused by a lack of apoceruloplasmin biosynthesis and copper metabolism is not disturbed (see <related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><italic toggle="yes">ATP7A</italic>-Related Copper Transport Disorders</related-object>).</p>
          </list-item>
        </list>
        <p>Aceruloplasminemia is characterized by marked iron accumulation in the brain as well as in the visceral tissues despite low serum iron concentrations. In these findings, aceruloplasminemia differs significantly from <related-object link-type="booklink" source-id="gene" document-id="hemochromatosis" document-type="chapter"><italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis</related-object>, the most common iron metabolic disorder.</p>
        <list list-type="bullet">
          <list-item>
            <p>Because aceruloplasminemia has features of Wilson disease and <italic toggle="yes">HFE</italic>-associated hereditary hemochromatosis, it could be incorrectly diagnosed as "mild hemochromatosis with hypoceruloplasminemia" or "mild Wilson disease with hemosiderosis."</p>
          </list-item>
        </list>
        <p>Ceruloplasmin synthesis can be reduced with acute liver failure or decompensated cirrhosis of any etiology. Decreased serum concentrations of ceruloplasmin are observed in protein-losing enteropathy, nephrotic syndrome, and malnutrition.</p>
        <p>Differential diagnoses for the neurologic manifestations of aceruloplasminemia include <related-object link-type="booklink" source-id="gene" document-id="huntington" document-type="chapter">Huntington disease</related-object>, <related-object link-type="booklink" source-id="gene" document-id="drpla" document-type="chapter">dentatorubral-pallidoluysian atrophy</related-object> (DRPLA), juvenile Parkinson disease including <related-object link-type="booklink" source-id="gene" document-id="jpd" document-type="chapter">Parkin type of early-onset Parkinson disease </related-object> (see also <related-object link-type="booklink" source-id="gene" document-id="parkinson-overview" document-type="chapter">Parkinson Disease Overview</related-object>), dystonia (see <related-object link-type="booklink" source-id="gene" document-id="dystonia-ov" document-type="chapter">Dystonia Overview</related-object>), drug effects or toxicity, and hereditary spinocerebellar ataxias (see <related-object link-type="booklink" source-id="gene" document-id="ataxias" document-type="chapter">Hereditary Ataxia Overview</related-object>).</p>
      </sec>
      <sec id="acp.Management">
        <title>Management</title>
        <sec id="acp.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with aceruloplasminemia, evaluations for the following are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Iron deposition.</bold> Serum ferritin concentration, brain and abdomen MRI findings, and hepatic iron and copper content by the liver biopsy</p>
            </list-item>
            <list-item>
              <p><bold>Neurologic findings.</bold> Brain MRI</p>
            </list-item>
            <list-item>
              <p><bold>Diabetes mellitus.</bold> Glucose tolerance test; blood concentrations of insulin and HbA1c</p>
            </list-item>
            <list-item>
              <p><bold>Retinal degeneration.</bold> Examination of the optic fundi and fluorescein angiography</p>
            </list-item>
            <list-item>
              <p><bold>Anemia.</bold> Complete blood count</p>
            </list-item>
            <list-item>
              <p><bold>Other.</bold> Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="acp.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Note: Individual case reports indicate the effectiveness of treatment in patients with aceruloplasminemia; however, no large series of symptomatic patients treated with iron chelators and zinc is available and there is no universally accepted treatment regimen. A systematic review/analysis of studies designed to evaluate the clinical effectiveness of desferrioxamine, deferiprone, deferasirox, and zinc as monotherapy for the initial treatment of various clinical presentations of aceruloplasminemia is needed.</p>
          <p><bold>Desferrioxamine.</bold> Treatment with iron chelating agents (i.e., desferrioxamine) can be considered for symptomatic individuals whose blood hemoglobin concentration is higher than 9 g/dL. Treatment can decrease serum ferritin concentration as well as brain and liver iron stores, and can prevent progression of the neurologic signs/symptoms [<xref ref-type="bibr" rid="acp.REF.miyajima.1997.404">Miyajima et al 1997</xref>].</p>
          <p>Intravenous infusions of 500 mg of desferrioxamine (desferoxamine mesylate) dissolved in 100 mL of isotonic saline solution are given over one hour. Desferrioxamine is infused twice a week for six to ten months.</p>
          <list list-type="bullet">
            <list-item>
              <p>In the <xref ref-type="bibr" rid="acp.REF.miyajima.1997.404">Miyajima et al [1997]</xref> study, head MRI evaluations were performed before and after treatment to evaluate the effect of treatment on iron storage in the brain. Serum concentrations of iron, ferritin, copper, hemoglobin, and hemoglobin A1c, as well as C-peptide immunoreactivity, were measured before and after treatment. Lipid peroxidation in plasma samples also was measured by the thiobarbituric acid method. T<sub>2</sub>-weighted MRI showed an increase in the signal intensity of the basal ganglia. Serum ferritin concentration was markedly reduced and hepatic iron concentration was decreased, whereas serum iron concentration was elevated and anemia and DM were ameliorated.</p>
            </list-item>
            <list-item>
              <p>In the <xref ref-type="bibr" rid="acp.REF.mariani.2004.756">Mariani et al [2004]</xref> report, the brain MRI did not change after more than one year of desferoxamine treatment, whereas excess iron in the liver was removed.</p>
            </list-item>
            <list-item>
              <p><xref ref-type="bibr" rid="acp.REF.pan.2011.2142">Pan et al [2011]</xref> reported an affected individual age 52 years who was treated with desferrioxamine (500 mg) by intravenous infusion in a 5% glucose solution once a week for four years. After four years of treatment, brain MRI evaluation demonstrated improvement in low-intensity areas in the basal ganglia, suggesting that iron chelation can reduce abnormal iron deposition in the central nervous system.</p>
            </list-item>
          </list>
          <p><bold>Deferasirox.</bold> Iron chelation therapy with deferasirox, an oral iron chelating agent, led to a mild improvement in clinical symptoms, including cognitive performance, gait, and balance, in an individual with aceruloplasminemia who had no response to both deferoxamine and fresh-frozen plasma therapy [<xref ref-type="bibr" rid="acp.REF.skidmore.2008.467">Skidmore et al 2008</xref>]. Oral administration of deferasirox may prevent tissue damage, particularly to the liver and pancreas [<xref ref-type="bibr" rid="acp.REF.finkenstedt.2010.1101">Finkenstedt et al 2010</xref>].</p>
          <p><bold>Deferiprone.</bold> This iron chelator has a lower molecular weight and more lipophilic properties. Deferiprone therapy had no beneficial effects in a patient in a previous report [<xref ref-type="bibr" rid="acp.REF.mariani.2004.756">Mariani et al 2004</xref>]; however, it has been shown to protect against retinal degeneration and neurodegeneration and to increase the life span if initiated early in mice exhibiting knockout for ceruloplasmin and hephaestin [<xref ref-type="bibr" rid="acp.REF.hadziahmetovic.2011.959">Hadziahmetovic et al 2011</xref>].</p>
          <p><bold>Fresh-frozen human plasma.</bold> After the intravenous administration of fresh-frozen human plasma (FFP) containing ceruloplasmin, serum iron content increases for several hours because of ferroxidase activity of ceruloplasmin. Iron content in the liver decreases more with the combined intravenous administration of FFP and desferrioxamine than with FFP administration alone. Neurologic signs/symptoms can improve following repetitive FFP treatment [<xref ref-type="bibr" rid="acp.REF.yonekawa.1999.157">Yonekawa et al 1999</xref>].</p>
          <p><bold>Antioxidants</bold> such as vitamin E may be used along with a chelator or oral administration of zinc to prevent tissue damage, particularly to the liver and pancreas [<xref ref-type="bibr" rid="acp.REF.kuhn.2007.450">Kuhn et al 2007</xref>].</p>
        </sec>
        <sec id="acp.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>Zinc concentrations in these patients were decreased in the brain and visceral organs, and zinc showed opposing distributions to those for iron. Because zinc has antioxidant activity, treatment with an iron chelator accompanied by zinc may be useful in patients with aceruloplasminemia to diminish iron accumulation in the brain and body and to prevent or ameliorate systemic and neurologic symptoms [<xref ref-type="bibr" rid="acp.REF.miyajima.2015.1011">Miyajima 2015</xref>].</p>
        </sec>
        <sec id="acp.Surveillance">
          <title>Surveillance</title>
          <p>Marked accumulation of iron in parenchymal tissues including the liver, pancreas, heart, and thyroid can result in diabetes mellitus, cardiac failure, and hypothyroidism.</p>
          <list list-type="bullet">
            <list-item>
              <p>All affected individuals should have an annual glucose tolerance test starting at age 15 years to evaluate for the onset of diabetes mellitus.</p>
            </list-item>
            <list-item>
              <p>ECG evaluation should be performed early in the course of the disease.</p>
            </list-item>
            <list-item>
              <p>Evaluation of thyroid and liver function and complete blood count are indicated annually starting at the time of diagnosis.</p>
            </list-item>
          </list>
        </sec>
        <sec id="acp.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p><bold>Iron supplements.</bold> Individuals with aceruloplasminemia erroneously diagnosed as having iron deficiency anemia and treated with iron supplements had accelerated iron accumulation.</p>
        </sec>
        <sec id="acp.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate apparently asymptomatic older and younger sibs of a proband (starting at age 15 years) in order to identify as early as possible those who would benefit from <xref ref-type="sec" rid="acp.Surveillance">surveillance</xref> and initiation of treatment. However, the proper preventive approach for asymptomatic sibs is unknown:</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known;</p>
            </list-item>
            <list-item>
              <p>Monitoring of serum concentrations of hemoglobin and hemoglobin A1c as anemia and diabetes may precede neurologic symptoms (see also <xref ref-type="sec" rid="acp.Surveillance">Surveillance</xref>).</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="acp.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="acp.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="acp.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="acp.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Aceruloplasminemia is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="acp.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an individual with aceruloplasminemia are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">CP</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Clinical disease is not known to occur in heterozygotes, although data are not adequate to exclude the possibility in older individuals</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) with clinical signs/symptoms have not been reported, although data are not adequate to exclude the possibility in older individuals.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> The offspring of an individual with aceruloplasminemia are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">CP</italic>.</p>
          <p><bold>Other family members of a proband.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">CP</italic> pathogenic variant.</p>
        </sec>
        <sec id="acp.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">CP</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="acp.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="acp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Testing of at-risk asymptomatic individuals.</bold> Consideration of molecular genetic testing of young, at-risk sibs is appropriate for guiding medical management (see Management, <xref ref-type="sec" rid="acp.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref>).</p>
          <p>Molecular genetic testing can be used with certainty to clarify the genetic status of at-risk family members if both <italic toggle="yes">CP</italic> pathogenic variants have been identified in an affected family member.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="acp.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">CP</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for aceruloplasminemia are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="acp.Resources">
        <title>Resources</title>
      </sec>
      <sec id="acp.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="acp.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Approximately 50 pathogenic variants have been identified [<xref ref-type="bibr" rid="acp.REF.kono.2012.1190">Kono 2012</xref>]. More than half of the pathogenic variants in <italic toggle="yes">CP</italic> are the pathogenic truncated variants leading to the formation of a premature stop codon. These pathogenic variants would be predicted to result in formation of a protein lacking the copper-binding sites presumed to be critical for enzymatic function. Molecular analysis of the pathogenic missense variants has shown several different mechanisms by which pathogenic variants in the ceruloplasmin gene can result in the lack of enzymatic activity (see <xref ref-type="fig" rid="acp.F2">Figure 2</xref>). Some mutated proteins are retained in the endoplasmic reticulum caused by defects in protein trafficking. Ceruloplasmin deficiency can arise through other mechanisms, either by indirect dysfunction of a copper-binding site or by other structural abnormalities in the protein that prevent the incorporation of copper into ceruloplasmin [<xref ref-type="bibr" rid="acp.REF.kono.2006.15">Kono &#x00026; Miyajima 2006</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">CP</italic> is approximately 4.4 kb in a total of 19 exons; it encodes the ceruloplasmin precursor. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="acp" object-id="acp.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic variants.</bold> More than 70 pathogenic variants in <italic toggle="yes">CP</italic> have been identified in over 60 affected families belonging to different racial groups [<xref ref-type="bibr" rid="acp.REF.yoshida.1995.267">Yoshida et al 1995</xref>, <xref ref-type="bibr" rid="acp.REF.yazaki.1998.30">Yazaki et al 1998</xref>, <xref ref-type="bibr" rid="acp.REF.miyajima.1999.617">Miyajima et al 1999</xref>, <xref ref-type="bibr" rid="acp.REF.daimon.2000.119">Daimon et al 2000</xref>, <xref ref-type="bibr" rid="acp.REF.hellman.2000.858">Hellman et al 2000</xref>, <xref ref-type="bibr" rid="acp.REF.kohno.2000.237">Kohno et al 2000</xref>, <xref ref-type="bibr" rid="acp.REF.bosio.2002.2246">Bosio et al 2002</xref>, <xref ref-type="bibr" rid="acp.REF.hellman.2002.1375">Hellman et al 2002</xref>, <xref ref-type="bibr" rid="acp.REF.lor_al.2002.851">Lor&#x000e9;al et al 2002</xref>, <xref ref-type="bibr" rid="acp.REF.hatanaka.2003.599">Hatanaka et al 2003</xref>, <xref ref-type="bibr" rid="acp.REF.mariani.2004.756">Mariani et al 2004</xref>, <xref ref-type="bibr" rid="acp.REF.kuhn.2005.111">Kuhn et al 2005</xref>, <xref ref-type="bibr" rid="acp.REF.p_rezaguilar.2005.947">P&#x000e9;rez-Aguilar et al 2005</xref>, <xref ref-type="bibr" rid="acp.REF.kono.2006a.361">Kono et al 2006a</xref>, <xref ref-type="bibr" rid="acp.REF.shang.2006.2217">Shang et al 2006</xref>, <xref ref-type="bibr" rid="acp.REF.kono.2012.1190">Kono 2012</xref>]. See <xref ref-type="fig" rid="acp.F3">Figure 3</xref>. No hot spots for pathogenic variants in <italic toggle="yes">CP</italic> have been observed.</p>
          <table-wrap id="acp.T.cp_pathogenic_variants_discussed_i" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p><italic toggle="yes">CP</italic> Pathogenic Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2962G&#x0003e;A</td>
                  <td headers="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly988Ser<break/>(Gly969Ser)</td>
                  <td headers="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_3" rowspan="2" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000096.3">NM_000096.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000087.1">NP_000087.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2991T&#x0003e;G</td>
                  <td headers="hd_h_acp.T.cp_pathogenic_variants_discussed_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.His997Gln<break/>(His978Gln)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the author. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="acp.TF.4.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions; in this instance the alias refers to the length of the mature peptide.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold> The product of <italic toggle="yes">CP</italic>, ceruloplasmin, is a blue copper oxidase that carries more than 95% of the plasma copper content in vertebrates.</p>
          <p>Ceruloplasmin has two forms: (1) a secreted form (1040 amino acids) mainly produced and secreted by hepatocytes; and, (2) a glycosylphosphatidylinositol (GPI)-anchored form (1065 amino acids) mainly expressed in astrocytes as well as visceral organs (see <xref ref-type="fig" rid="acp.F4">Figure 4</xref>) [<xref ref-type="bibr" rid="acp.REF.patel.2000.4305">Patel et al 2000</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>The secreted form, alpha2-glycoprotein, is synthesized mainly in the liver; it plays an important role in iron mobilization from the tissues as a ferroxidase.</p>
            </list-item>
            <list-item>
              <p>The GPI-anchored form is generated by alternative RNA splicing. The splicing occurs downstream of exon 18 and replaces the five C-terminal amino acids of the secreted form with an alternative 30-amino acid sequence that signals GPI anchor addition. The GPI-anchored form of ceruloplasmin is expressed in astrocytes and plays an important role in iron metabolism in the central nervous system through its ferroxidase activity [<xref ref-type="bibr" rid="acp.REF.jeong.2003.27144">Jeong &#x00026; David 2003</xref>].</p>
            </list-item>
          </list>
          <p><bold>Abnormal gene product.</bold> Abnormal gene products are usually degraded immediately after release from the hepatocytes. With some pathogenic nonsense <italic toggle="yes">CP</italic> variants, abnormal ceruloplasmin is retained within the endoplasmic reticulum (early secretory pathway); and, with other pathogenic variants, abnormal ceruloplasmin results in decreased copper incorporation into ceruloplasmin in the Golgi apparatus (late secretory pathway) [<xref ref-type="bibr" rid="acp.REF.hellman.2002.1375">Hellman et al 2002</xref>, <xref ref-type="bibr" rid="acp.REF.kono.2006.15">Kono &#x00026; Miyajima 2006</xref>, <xref ref-type="bibr" rid="acp.REF.kono.2006a.361">Kono et al 2006a</xref>]. In <italic toggle="yes">CP</italic>-null mice, different mechanisms could underlie the loss of astrocytes and neurons [<xref ref-type="bibr" rid="acp.REF.jeong.2006.9810">Jeong &#x00026; David 2006</xref>].</p>
        </sec>
      </sec>
      <sec id="acp.References">
        <title>References</title>
        <sec id="acp.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="acp.Literature_Cited.reflist0">
            <ref id="acp.REF.bosio.2002.2246">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bosio</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Gobbi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roetto</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zecchina</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonardo</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rizzetto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucetti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petrozzi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonuccelli</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camaschella</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Anemia and iron overload due to compound heterozygosity for novel ceruloplasmin mutations.</article-title>
                <source>Blood</source>
                <volume>100</volume>
                <fpage>2246</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12200392</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.daimon.2000.119">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daimon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Susa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohizumi</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moriai</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawanami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohnuma</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Igarashi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>A novel mutation of the ceruloplasmin gene in a patient with heteroallelic ceruloplasmin gene mutation (HypoCPGM).</article-title>
                <source>Tohoku J Exp Med</source>
                <volume>191</volume>
                <fpage>119</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">10997552</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.daimon.1997.678">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Daimon</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamatani</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tominaga</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manaka</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaki</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>NIDDM with a ceruloplasmin gene mutation.</article-title>
                <source>Diabetes Care</source>
                <volume>20</volume>
                <fpage>678</fpage>
                <pub-id pub-id-type="pmid">9097006</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.dunaief.2005.1062">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dunaief</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Richa</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franks</surname>
                    <given-names>EP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schultze</surname>
                    <given-names>RL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aleman</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schenck</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zimmerman</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brooks</surname>
                    <given-names>DG</given-names>
                  </name>
                </person-group>
                <article-title>Macular degeneration in a patient with aceruloplasminemia, a disease associated with retinal iron overload.</article-title>
                <source>Ophthalmology.</source>
                <year>2005</year>
                <volume>112</volume>
                <fpage>1062</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15882908</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.erel.1998.2313">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Erel</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Automated measurement of serum ferroxidase activity.</article-title>
                <source>Clin Chem</source>
                <volume>44</volume>
                <fpage>2313</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9799759</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.finkenstedt.2010.1101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Finkenstedt</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofner</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasser</surname>
                    <given-names>BI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakry</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Creus</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremser</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schocke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theurl</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moser</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schranz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonn</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poewe</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogel</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janecke</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zoller</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation</article-title>
                <source>J Hepatol</source>
                <volume>53</volume>
                <fpage>1101</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20801540</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.hadziahmetovic.2011.959">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hadziahmetovic</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolkow</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lacovelli</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grieco</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lyubarsky</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pratico</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Connelly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spino</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harris</surname>
                    <given-names>ZL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunaief</surname>
                    <given-names>JL</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>The oral iron chelator deferiprone protects against iron overload-induced retinal degeneration.</article-title>
                <source>Invest Ophthalmol Vis Sci</source>
                <volume>52</volume>
                <fpage>959</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">21051716</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.hatanaka.2003.599">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hatanaka</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okano</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Aceruloplasminemia with juvenile-onset diabetes mellitus caused by exon skipping in the ceruloplasmin gene.</article-title>
                <source>Intern Med</source>
                <volume>42</volume>
                <fpage>599</fpage>
                <lpage>604</lpage>
                <pub-id pub-id-type="pmid">12879954</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.hayflick.2003.33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ching</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitschier</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Genetic, clinical, and radiographic delineation of Hallervorden-Spatz syndrome.</article-title>
                <source>N Engl J Med</source>
                <volume>348</volume>
                <fpage>33</fpage>
                <lpage>40</lpage>
                <pub-id pub-id-type="pmid">12510040</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.hellman.2002.1375">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hellman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitlin</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Biochemical analysis of a missense mutation in aceruloplasminemia.</article-title>
                <source>J Biol Chem</source>
                <volume>277</volume>
                <fpage>1375</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">11689569</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.hellman.2000.858">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hellman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gehrke</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stegen</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffman</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitlin</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stremmel</surname>
                    <given-names>W</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Hepatic iron overload in aceruloplasminaemia.</article-title>
                <source>Gut</source>
                <volume>47</volume>
                <fpage>858</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">11076887</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.jeong.2003.27144">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jeong</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system.</article-title>
                <source>J Biol Chem</source>
                <volume>278</volume>
                <fpage>27144</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">12743117</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.jeong.2006.9810">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jeong</surname>
                    <given-names>SY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Age-related changes in iron homeostasis and cell death in the cerebellum of ceruloplasmin-deficient mice.</article-title>
                <source>J Neurosci</source>
                <volume>26</volume>
                <fpage>9810</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16988052</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kaneko.2002.1069">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arima</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohara</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>SI</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Astrocytic deformity and globular structures are characteristic of the brains of patients with aceruloplasminemia.</article-title>
                <source>J Neuropathol Exp Neurol</source>
                <volume>61</volume>
                <fpage>1069</fpage>
                <lpage>77</lpage>
                <pub-id pub-id-type="pmid">12484569</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kohno.2000.237">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inoue</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Aceruloplasminemia with a novel mutation associated with parkinsonism.</article-title>
                <source>Neurogenetics</source>
                <volume>2</volume>
                <fpage>237</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">10983721</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kono.2012.1190">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Aceruloplasminemia.</article-title>
                <source>Curr Drug Targets.</source>
                <volume>13</volume>
                <fpage>1190</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">22515740</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kono.2006.15">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Molecular and pathological basis of aceruloplasminemia.</article-title>
                <source>Biol Res</source>
                <volume>39</volume>
                <fpage>15</fpage>
                <lpage>23</lpage>
                <pub-id pub-id-type="pmid">16629161</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kono.2015">
              <mixed-citation publication-type="book">Kono S, Miyajima H. Aceruloplasminemia. In: Rosenberg RN, Pascual JM, eds. <italic toggle="yes">Rosenberg&#x02019;s Molecular and Genetic Basis of Neurological and Psychiatric Disease.</italic> 5 ed. Elsevier, Academic Press. 2015:495-506.</mixed-citation>
            </ref>
            <ref id="acp.REF.kono.2006a.361">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oda</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ishikawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kitagawa</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006a</year>
                <article-title>Biochemical features of ceruloplasmin gene mutations linked to aceruloplasminemia.</article-title>
                <source>Neuromolecular Med</source>
                <volume>8</volume>
                <fpage>361</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">16775387</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kono.2006b.240">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suzuki</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shirakawa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Murakawa</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2006b</year>
                <article-title>Hepatic iron overload associated with a decreased serum ceruloplasmin level in a novel clinical type of aceruloplasminemia.</article-title>
                <source>Gastroenterology</source>
                <volume>131</volume>
                <fpage>240</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16831606</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kuhn.2007.450">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bewermeyer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>KF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoogenraad</surname>
                    <given-names>TU</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Treatment of symptomatic heterozygous aceruloplasminemia with oral zinc sulphate.</article-title>
                <source>Brain Dev</source>
                <volume>29</volume>
                <fpage>450</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">17307325</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.kuhn.2005.111">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunath</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartmann-Klosterkoetter</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cooper-Mahkorn</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bewermeyer</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Extrapyramidal and cerebellar movement disorder in association with heterozygous ceruloplasmin gene mutation.</article-title>
                <source>J Neurol</source>
                <volume>252</volume>
                <fpage>111</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15654567</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.lor_al.2002.851">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lor&#x000e9;al</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turlin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pigeon</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moisan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ropert</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morice</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gandon</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jouanolle</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hider</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brissot</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Aceruloplasminemia: new clinical, pathophysiological and therapeutic insights.</article-title>
                <source>J Hepatol</source>
                <volume>36</volume>
                <fpage>851</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12044538</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.mariani.2004.756">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mariani</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arosio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pelucchi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grisoli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trombini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Piperno</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Iron chelation therapy in aceruloplasminaemia: study of a patient with a novel missense mutation.</article-title>
                <source>Gut</source>
                <volume>53</volume>
                <fpage>756</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15082597</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.miyajima.2003.345">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Aceruloplasminemia, an iron metabolic disorder.</article-title>
                <source>Neuropathology</source>
                <year>2003</year>
                <volume>23</volume>
                <fpage>345</fpage>
                <lpage>50</lpage>
                <pub-id pub-id-type="pmid">14719552</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.miyajima.2015.1011">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Investigated and available therapeutic options for treating aceruloplasminemia.</article-title>
                <source>Expert Opin Orphan Drugs.</source>
                <year>2015</year>
                <volume>3</volume>
                <fpage>1011</fpage>
                <lpage>20</lpage>
              </element-citation>
            </ref>
            <ref id="acp.REF.miyajima.1999.617">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yonekawa</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kanno</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Estimation of the gene frequency of aceruloplasminemia in Japan.</article-title>
                <source>Neurology</source>
                <volume>53</volume>
                <fpage>617</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">10449129</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.miyajima.1987.761">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishimura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mizoguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakamoto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Honda</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1987</year>
                <article-title>Familial apoceruloplasmin deficiency associated with blepharospasm and retinal degeneration.</article-title>
                <source>Neurology</source>
                <volume>37</volume>
                <fpage>761</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">3574673</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.miyajima.1997.404">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kamata</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sakai</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitlin</surname>
                    <given-names>JD</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Use of desferrioxamine in the treatment of aceruloplasminemia.</article-title>
                <source>Ann Neurol</source>
                <volume>41</volume>
                <fpage>404</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">9066364</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.miyajima.2003.205">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kono</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Aceruloplasminemia, an inherited disorder of iron metabolism.</article-title>
                <source>Biometals</source>
                <volume>16</volume>
                <fpage>205</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">12572680</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.oide.2006.170">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Oide</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaneko</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arima</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Iron overload and antioxidative role of perivascular astrocytes in aceruloplasminemia.</article-title>
                <source>Neuropathol Appl Neurobiol</source>
                <volume>32</volume>
                <fpage>170</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16599945</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.pan.2011.2142">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pan</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>HH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shang</surname>
                    <given-names>HF</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up.</article-title>
                <source>Mov Disord.</source>
                <volume>26</volume>
                <fpage>2142</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21594898</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.patel.2000.4305">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Patel</surname>
                    <given-names>BN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunn</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>David</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain.</article-title>
                <source>J Biol Chem</source>
                <volume>275</volume>
                <fpage>4305</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">10660599</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.p_rezaguilar.2005.947">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;rez-Aguilar</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burguera</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Benlloch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berenguer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rayon</surname>
                    <given-names>JM</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Aceruloplasminemia in an asymptomatic patient with a new mutation. Diagnosis and family genetic analysis.</article-title>
                <source>J Hepatol</source>
                <volume>42</volume>
                <fpage>947</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15885371</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.shang.2006.2217">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shang</surname>
                    <given-names>HF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jiang</surname>
                    <given-names>XF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgunder</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Novel mutation in the ceruloplasmin gene causing a cognitive and movement disorder with diabetes mellitus.</article-title>
                <source>Mov Disord</source>
                <volume>21</volume>
                <fpage>2217</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">17013908</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.skidmore.2008.467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Skidmore</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drago</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Foster</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmalfuss</surname>
                    <given-names>IM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heilman</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Streiff</surname>
                    <given-names>RR</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Aceruloplasminaemia with progressive atrophy without brain iron overload: treatment with oral chelation.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>79</volume>
                <fpage>467</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">17911185</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.takeuchi.2002.543">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Takeuchi</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshikawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsujino</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukamoto</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shiroi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kikuchi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fukui</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>A case of aceruloplasminaemia: abnormal serum ceruloplasmin protein without ferroxidase activity.</article-title>
                <source>J Neurol Neurosurg Psychiatry</source>
                <volume>72</volume>
                <fpage>543</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11909923</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.yamaguchi.1998.11">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yamaguchi</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takahashi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kawanami</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sasaki</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Retinal degeneration in hereditary ceruloplasmin deficiency.</article-title>
                <source>Ophthalmologica</source>
                <volume>212</volume>
                <fpage>11</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9438577</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.yazaki.1998.30">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yazaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furihata</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yonekawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okabe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamashita</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>A novel splicing mutation in the ceruloplasmin gene responsible for hereditary ceruloplasmin deficiency with hemosiderosis.</article-title>
                <source>J Neurol Sci</source>
                <volume>156</volume>
                <fpage>30</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">9559983</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.yonekawa.1999.157">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yonekawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okabe</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Asamoto</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohta</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>A case of hereditary ceruloplasmin deficiency with iron deposition in the brain associated with chorea, dementia, diabetes mellitus and retinal pigmentation: administration of fresh-frozen human plasma.</article-title>
                <source>Eur Neurol</source>
                <volume>42</volume>
                <fpage>157</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">10529542</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.yoshida.1995.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yoshida</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furihata</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Takeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamamoto</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morita</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hiyamuta</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ikeda</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shimizu</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yanagisawa</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>1995</year>
                <article-title>A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans.</article-title>
                <source>Nat Genet</source>
                <volume>9</volume>
                <fpage>267</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">7539672</pub-id>
              </element-citation>
            </ref>
            <ref id="acp.REF.zhou.2001.345">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zhou</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Westaway</surname>
                    <given-names>SK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levinson</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gitschier</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hayflick</surname>
                    <given-names>SJ</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome.</article-title>
                <source>Nat Genet</source>
                <volume>28</volume>
                <fpage>345</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11479594</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="acp.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="acp.Suggested_Reading.reflist0">
            <ref id="acp.REF.mcneill.2008.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McNeill</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pandolfo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuhn</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shang</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miyajima</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>The neurological presentation of ceruloplasmin gene mutations.</article-title>
                <source>Eur Neurol</source>
                <volume>60</volume>
                <fpage>200</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">18667828</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="acp.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="acp.Acknowledgments">
          <title>Acknowledgments</title>
          <p>Aceruloplasminemia research is funded in part by a Grant-in-Aid of Science from the Ministry of Education, Science, Culture, Sports, and Technology, Japan.</p>
        </sec>
        <sec id="acp.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>5 November 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>18 April 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>17 February 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>29 April 2008 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>15 August 2005 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>12 August 2003 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>23 June 2003 (hm) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="acp.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>CT and T<sub>1</sub>- and T<sub>2</sub>-weighted MRI of an individual with aceruloplasminemia. CT (A, D), T<sub>2</sub>- (B, E) and T<sub>1</sub>- (C) weighted axial images of the brain (upper row) and abdomen (bottom row). Brain and abdomen CT show abnormal high-density areas in the basal ganglia and liver. MRI shows signal attenuation of the basal ganglia and thalamus as well as liver.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="acp-Image001" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="acp.F2" orientation="portrait">
          <label>Figure 2. </label>
          <caption>
            <p>Ceruloplasmin (Cp) biosynthesis. Several different mechanisms by which <italic toggle="yes">CP</italic> pathogenic missense variants result in the lack of enzymatic activity. As p.Pro177Arg, p.Gly176Arg, and p.Ile9Phe mutated protein is retained in the endoplasmic reticulum, aceruloplasminemia is caused by defects in protein trafficking. Pathogenic variants p.Gly631Arg, p.Ala331Asp, and p.Met966Val cause CP deficiency through other mechanisms: indirect dysfunction of a copper-binding site or other structural abnormalities in the protein that prevent the incorporation of copper (Cu) into CP. Protein variant p.His978Gln has no ferroxidase activity. Protein variants p.Gln146Glu and p.Gly876Ala degrade rapidly when holoceruloplasmin is secreted into the extra-cellular space. In this figure, the numbering of amino acid residues is based on the mature protein after cleavage of the 19-amino acid signal peptide.Note: Pathogenic variants and their nomenclature in <xref ref-type="fig" rid="acp.F2">Figure 2</xref> were provided by the author (H Miyajima) and not reviewed by <italic toggle="yes">GeneReviews</italic> staff.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="acp-Image002" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="acp.F3" orientation="portrait">
          <label>Figure 3. </label>
          <caption>
            <p>Pathogenic variants (mutations) characterized in individuals with aceruloplasminemia and their family members. The structure of the human ceruloplasmin gene consists of 20 exons (exon numbering based on <xref ref-type="bibr" rid="acp.REF.kono.2015">Kono &#x00026; Miyajima [2015]</xref>). Alternative splicing at exon 18 (see <xref ref-type="fig" rid="acp.F4">Figure 4</xref>) allows for the secreted type or GPI-linked type of ceruloplasmin isoforms, as indicated. The indicated pathogenic variants are referenced in the text and some are included in the Author&#x02019;s unpublished data. In this figure, the numbering of amino acid residues is based on the mature protein after cleavage of the 19-amino acid signal peptide.From Kono S &#x00026; Miyajima H [2015] Note: Pathogenic variants and their nomenclature in <xref ref-type="fig" rid="acp.F3">Figure 3</xref> were provided by the author (H Miyajima) and not reviewed by <italic toggle="yes">GeneReviews</italic> staff.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="acp-Image003" position="anchor" orientation="portrait"/>
        </fig>
        <fig position="float" id="acp.F4" orientation="portrait">
          <label>Figure 4. </label>
          <caption>
            <p>The secreted and GPI-anchored forms of ceruloplasmin generated by alternative splicing. Northern blot analyses of two forms of ceruloplasmin in the organs (lane 1: brain; lane 2: lung; lane 3: liver; lane 4: heart; lane 5: kidney; lane 6: pancreas).</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="acp-Image004" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
